|| Securities, Pre-IPO / Grey Market
|| Asking Price
|| AUD 6M shares @ $0.14 per share (cum rights) = 24.32% discount to December 2016 Pre-IPO Rights Issue
Sale of pre-IPO existing shares by a motivated Seller in a public, unlisted Company based in Melbourne, Australia. Since 2007, the Company has successfully
realised IP value in telomerase-based diagnostics to effectively identify bladder cancer. In 2016 it transitioned from a purely R&D company to
a commercial entity with product revenues. Has recently formalised distribution agreements for US and UK markets. Since inception, the Company has
raised A$16.1M in equity to successfully achieve milestones and has been well supported by considerable R&D Incentives.
Share this Listing